Clinical & Experimental Metastasis最新文献

筛选
英文 中文
Etiology and treatment of cancer-related secondary lymphedema. 癌症相关继发性淋巴水肿的病因及治疗。
IF 4.2 3区 医学
Clinical & Experimental Metastasis Pub Date : 2024-08-01 Epub Date: 2023-09-30 DOI: 10.1007/s10585-023-10232-8
Michael Bernas, Sara Al-Ghadban, Saskia R J Thiadens, Karen Ashforth, Walter C Lin, Bauback Safa, Rudolf Buntic, Michael Paukshto, Alexandra Rovnaya, Margaret L McNeely
{"title":"Etiology and treatment of cancer-related secondary lymphedema.","authors":"Michael Bernas, Sara Al-Ghadban, Saskia R J Thiadens, Karen Ashforth, Walter C Lin, Bauback Safa, Rudolf Buntic, Michael Paukshto, Alexandra Rovnaya, Margaret L McNeely","doi":"10.1007/s10585-023-10232-8","DOIUrl":"10.1007/s10585-023-10232-8","url":null,"abstract":"<p><p>Lymphedema and specifically cancer-related lymphedema is not the main focus for both patients and physicians dealing with cancer. Its etiology is an unfortunate complication of cancer treatment. Although lymphedema treatments have gained an appreciable consensus, many practitioners have developed and prefer their own specific protocols and this is especially true for conventional (manual) versus surgical treatments. This collection of presentations explores the incidence and genetics of cancer-related lymphedema, early detection and monitoring techniques, both conventional and operative treatment options, and the importance and role of exercise for patients with cancer-related lymphedema. These assembled presentations provide valuable insights into the challenges and opportunities presented by cancer-related lymphedema including the latest research, treatments, and exercises available to improve patient outcomes and quality of life.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41112154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular mechanisms of sensitivity and resistance to radiotherapy. 放疗敏感性和耐药性的分子机制。
IF 4.2 3区 医学
Clinical & Experimental Metastasis Pub Date : 2024-08-01 Epub Date: 2024-01-17 DOI: 10.1007/s10585-023-10260-4
Jessica L Xing, Baldassarre Stea
{"title":"Molecular mechanisms of sensitivity and resistance to radiotherapy.","authors":"Jessica L Xing, Baldassarre Stea","doi":"10.1007/s10585-023-10260-4","DOIUrl":"10.1007/s10585-023-10260-4","url":null,"abstract":"<p><p>The molecular mechanisms underlying sensitivity and resistance to radiotherapy is an area of active investigation and discovery as its clinical applications have the potential to improve cancer patients' outcomes. In addition to the traditional pathways of radiation biology, our knowledge now includes molecular pathways of radiation sensitivity and resistance which have provided insights into potential targets for enhancing radiotherapy efficacy. Sensitivity to radiotherapy is influenced by the intricate interplay of various molecular mechanisms involved in DNA damage repair, apoptosis, cellular senescence, and epigenetics. Translationally, there have been several successful applications of this new knowledge into the clinic, such as biomarkers for improved response to chemo-radiation. New therapies to modify radiation response, such as the poly (ADP-ribose) polymerase (PARP) inhibitors, derived from research on DNA repair pathways leading to radiotherapy resistance, are being used clinically. In addition, p53-mediated pathways are critical for DNA damage related apoptosis, cellular senescence, and cell cycle arrest. As the understanding of genetic markers, molecular profiling, molecular imaging, and functional assays improve, these advances once translated clinically, will help propel modern radiation therapy towards more precise and individualized practices.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139478108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of CTC discoveries for liquid biopsy: the RPL/RPS gene signature of melanoma CTCs is linked to brain metastasis onset. 将发现的 CTC 应用于液体活检:黑色素瘤 CTC 的 RPL/RPS 基因特征与脑转移的发生有关。
IF 4.2 3区 医学
Clinical & Experimental Metastasis Pub Date : 2024-08-01 Epub Date: 2024-01-12 DOI: 10.1007/s10585-023-10255-1
Tetiana Y Bowley, Dario Marchetti
{"title":"Application of CTC discoveries for liquid biopsy: the RPL/RPS gene signature of melanoma CTCs is linked to brain metastasis onset.","authors":"Tetiana Y Bowley, Dario Marchetti","doi":"10.1007/s10585-023-10255-1","DOIUrl":"10.1007/s10585-023-10255-1","url":null,"abstract":"","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139424318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvant therapy for resectable melanoma. 可切除黑色素瘤的新辅助治疗。
IF 4.2 3区 医学
Clinical & Experimental Metastasis Pub Date : 2024-08-01 Epub Date: 2024-01-28 DOI: 10.1007/s10585-023-10263-1
Cimarron E Sharon, Giorgos C Karakousis
{"title":"Neoadjuvant therapy for resectable melanoma.","authors":"Cimarron E Sharon, Giorgos C Karakousis","doi":"10.1007/s10585-023-10263-1","DOIUrl":"10.1007/s10585-023-10263-1","url":null,"abstract":"<p><p>The standard of care for patients with resectable stage III/IV melanoma classically included upfront resection with adjuvant therapy. However, in more recent years, the amount of systemic therapies available for neoadjuvant use for these patients has increased. This article reviewed clinical trials investigating neoadjuvant therapy for patients with resectable stage III/IV melanoma. The outcomes of these trials have identified optimal treatment regimens to maximise patient response and minimize toxicities. Additionally, the date demonstrate advantages to neoadjuvant treatment compared to adjuvant therapy alone. Further research is needed to utilize a patient's response to neoadjuvant treatment for prognostication and creation of an individualized treatment plan.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11283575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139569970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sentinel lymph nodes in melanoma: necessary as ever for optimal treatment. 黑色素瘤前哨淋巴结:最佳治疗的必要条件。
IF 4.2 3区 医学
Clinical & Experimental Metastasis Pub Date : 2024-08-01 Epub Date: 2024-01-02 DOI: 10.1007/s10585-023-10254-2
Mark B Faries
{"title":"Sentinel lymph nodes in melanoma: necessary as ever for optimal treatment.","authors":"Mark B Faries","doi":"10.1007/s10585-023-10254-2","DOIUrl":"10.1007/s10585-023-10254-2","url":null,"abstract":"<p><p>Lymphatic metastasis is the dominant route of initial spread for most solid tumors. For many such malignancies, including melanomas, surgical treatment previously included removal of all potentially draining regional lymph nodes (elective node dissection). The advent of lymphatic mapping and sentinel lymph node (SLN) biopsy allowed accurate pathologic assessment of the metastatic status of regional nodes and spared patients full dissection if their SLN was clear. In melanoma, recent clinical research has demonstrated that complete lymph node dissection is not clinically beneficial, even for patients with sentinel node metastases and that patients with high-risk primary melanomas benefit from adjuvant systemic immunotherapy, even without nodal disease. These two changes in the standard of care have led to some interest in abandoning surgical nodal staging via the sentinel lymph node biopsy procedure. However, this appears to be premature and potentially detrimental to optimal patient management. The ongoing value of sentinel node biopsy stems from its ability to provide critically important prognostic information as well as durable regional nodal disease control for most patients with nodal metastases, even in the absence of complete dissection of the basin. It also provides an opportunity to identify novel prognostic and predictive immunologic and molecular biomarkers. While it is certainly possible that additional changes in melanoma therapy will make sentinel lymph node biopsy obsolete in the future, at present it remains a minimally invasive, low morbidity means of improving both staging and outcomes.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11374908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139080508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: CXCL2-CXCR2 axis mediates αV integrin-dependent peritoneal metastasis of colon cancer cells 更正:CXCL2-CXCR2轴介导结肠癌细胞的αV整合素依赖性腹膜转移
IF 4 3区 医学
Clinical & Experimental Metastasis Pub Date : 2024-07-27 DOI: 10.1007/s10585-024-10302-5
Mattias Lepsenyi, Nader Algethami, Amr A. Al-Haidari, Anwar Algaber, Ingvar Syk, Milladur Rahman, Henrik Thorlacius
{"title":"Correction: CXCL2-CXCR2 axis mediates αV integrin-dependent peritoneal metastasis of colon cancer cells","authors":"Mattias Lepsenyi, Nader Algethami, Amr A. Al-Haidari, Anwar Algaber, Ingvar Syk, Milladur Rahman, Henrik Thorlacius","doi":"10.1007/s10585-024-10302-5","DOIUrl":"https://doi.org/10.1007/s10585-024-10302-5","url":null,"abstract":"","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141781046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Forty years on: a brief history of clinical and experimental metastasis. 四十年:临床和实验转移简史。
IF 4.2 3区 医学
Clinical & Experimental Metastasis Pub Date : 2024-06-01 Epub Date: 2024-03-23 DOI: 10.1007/s10585-024-10281-7
Jonathan P Sleeman, Jörg Haier
{"title":"Forty years on: a brief history of clinical and experimental metastasis.","authors":"Jonathan P Sleeman, Jörg Haier","doi":"10.1007/s10585-024-10281-7","DOIUrl":"10.1007/s10585-024-10281-7","url":null,"abstract":"","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11213719/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140193512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Membrane Lipid Replacement for reconstituting mitochondrial function and moderating cancer-related fatigue, pain and other symptoms while counteracting the adverse effects of cancer cytotoxic therapy. 膜脂替代物用于重建线粒体功能,缓解癌症相关的疲劳、疼痛和其他症状,同时抵消癌症细胞毒疗法的不良影响。
IF 4.2 3区 医学
Clinical & Experimental Metastasis Pub Date : 2024-06-01 Epub Date: 2024-06-16 DOI: 10.1007/s10585-024-10290-6
Garth L Nicolson, Gonzalo Ferreira de Mattos
{"title":"Membrane Lipid Replacement for reconstituting mitochondrial function and moderating cancer-related fatigue, pain and other symptoms while counteracting the adverse effects of cancer cytotoxic therapy.","authors":"Garth L Nicolson, Gonzalo Ferreira de Mattos","doi":"10.1007/s10585-024-10290-6","DOIUrl":"10.1007/s10585-024-10290-6","url":null,"abstract":"<p><p>Cancer-related fatigue, pain, gastrointestinal and other symptoms are among the most familiar complaints in practically every type and stage of cancer, especially metastatic cancers. Such symptoms are also related to cancer oxidative stress and the damage instigated by cancer cytotoxic therapies to cellular membranes, especially mitochondrial membranes. Cancer cytotoxic therapies (chemotherapy and radiotherapy) often cause adverse symptoms and induce patients to terminate their anti-neoplastic regimens. Cancer-related fatigue, pain and other symptoms and the adverse effects of cancer cytotoxic therapies can be safely moderated with oral Membrane Lipid Replacement (MLR) glycerolphospholipids and mitochondrial cofactors, such as coenzyme Q<sub>10</sub>. MLR provides essential membrane lipids and precursors to maintain mitochondrial and other cellular membrane functions and reduces fatigue, pain, gastrointestinal, inflammation and other symptoms. In addition, patients with a variety of chronic symptoms benefit from MLR supplements, and MLR also has the ability to enhance the bioavailability of nutrients and slowly remove toxic, hydrophobic molecules from cells and tissues.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141327275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Poor patient outcome correlates with active engulfment of cytokeratin positive CTCs within cancer-associated monocyte population in lung cancer. 肺癌患者的不良预后与癌症相关单核细胞群中细胞角蛋白阳性 CTC 的主动吞噬有关。
IF 4.2 3区 医学
Clinical & Experimental Metastasis Pub Date : 2024-06-01 Epub Date: 2024-02-28 DOI: 10.1007/s10585-024-10270-w
A P Wiegmans, E Ivanova, V Y Naei, J Monkman, J Fletcher, W Mullally, M E Warkiani, K O'Byrne, A Kulasinghe
{"title":"Poor patient outcome correlates with active engulfment of cytokeratin positive CTCs within cancer-associated monocyte population in lung cancer.","authors":"A P Wiegmans, E Ivanova, V Y Naei, J Monkman, J Fletcher, W Mullally, M E Warkiani, K O'Byrne, A Kulasinghe","doi":"10.1007/s10585-024-10270-w","DOIUrl":"10.1007/s10585-024-10270-w","url":null,"abstract":"<p><p>High rates of mortality in non-small cell lung cancer lung cancer is due to inherent and acquired resistance to systemic therapies and subsequent metastatic burden. Metastasis is supported by suppression of the immune system at secondary organs and within the circulation. Modulation of the immune system is now being exploited as a therapeutic target with immune checkpoint inhibitors. The tracking of therapeutic efficacy in a real-time can be achieved with liquid biopsy, and evaluation of circulating tumour cells and the associated immune cells. A stable liquid biopsy biomarker for non-small cell lung cancer lung cancer has yet to be approved for clinical use. We performed a cross-sectional single-site study, and collected liquid biopsies from patients diagnosed with early, locally advanced, or metastatic lung cancer, undergoing surgery, or systemic therapy (chemotherapy/checkpoint inhibitors). Evaluation of overall circulating tumour cell counts, or cluster counts did not correlate with patient outcome. Interestingly, the numbers of Pan cytokeratin positive circulating tumour cells engulfed by tumour associated monocytes correlated strongly with patient outcome independent of circulating tumour cell counts and the use of checkpoint inhibitors. We suggest that Pan cytokeratin staining within monocytes is an important indicator of tumour-associated inflammation post-therapy and an effective biomarker with strong prognostic capability for patient outcome.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11213738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139982510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glycosylation profiles of breast cancer cells may represent clonal variations of multiple organ metastases. 乳腺癌细胞的糖基化特征可能代表多器官转移的克隆变异。
IF 4.2 3区 医学
Clinical & Experimental Metastasis Pub Date : 2024-06-01 Epub Date: 2024-01-09 DOI: 10.1007/s10585-023-10253-3
Yoshiya Horimoto, May Thinzar Hlaing, Harumi Saeki, Kaori Denda-Nagai, Katrin Ishii-Schrade, Haruhiko Fujihira, Masaaki Abe, Miki Noji, Shigeyuki Shichino, Mitsue Saito, Tatsuro Irimura
{"title":"Glycosylation profiles of breast cancer cells may represent clonal variations of multiple organ metastases.","authors":"Yoshiya Horimoto, May Thinzar Hlaing, Harumi Saeki, Kaori Denda-Nagai, Katrin Ishii-Schrade, Haruhiko Fujihira, Masaaki Abe, Miki Noji, Shigeyuki Shichino, Mitsue Saito, Tatsuro Irimura","doi":"10.1007/s10585-023-10253-3","DOIUrl":"10.1007/s10585-023-10253-3","url":null,"abstract":"<p><p>Glycosylation changes of cancer cells are known to be associated with malignant progression and metastases and potentially determine the organ-selective nature of metastasis as theorized by Paget (Lancet 1:571-573, 1889). Cellular glycans play a variety of roles in the processes of metastasis and may be unique to the cells that metastasize to different organs. We analyzed the glycosylation profiles of the primary tumor and tumors metastasized to lymph node, liver, lung, brain, bone, thyroid, kidney, adrenal, small intestine and pancreas in an autopsy case of breast cancer employing a lectin microarray with 45 lectins. Clustering analysis of the data revealed that metastatic breast cancer cells were categorized into several clusters according to their glycosylation profiles. Our results provide a biological basis to understand differential phenotypes of metastatic breast cancer cells potentially reflecting clonal origin, which does not directly reflect genomic or genetic changes or microenvironmental effects but connects to glycosylation profiles.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信